33 research outputs found

    Learning Social Affordance Grammar from Videos: Transferring Human Interactions to Human-Robot Interactions

    Full text link
    In this paper, we present a general framework for learning social affordance grammar as a spatiotemporal AND-OR graph (ST-AOG) from RGB-D videos of human interactions, and transfer the grammar to humanoids to enable a real-time motion inference for human-robot interaction (HRI). Based on Gibbs sampling, our weakly supervised grammar learning can automatically construct a hierarchical representation of an interaction with long-term joint sub-tasks of both agents and short term atomic actions of individual agents. Based on a new RGB-D video dataset with rich instances of human interactions, our experiments of Baxter simulation, human evaluation, and real Baxter test demonstrate that the model learned from limited training data successfully generates human-like behaviors in unseen scenarios and outperforms both baselines.Comment: The 2017 IEEE International Conference on Robotics and Automation (ICRA

    Learning and Inferring “Dark Matter” and Predicting Human Intents and Trajectories in Videos

    No full text

    Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19

    No full text
    Lopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral effects and safety of lopinavir/ritonavir and arbidol in patients with the 2019-nCoV disease (COVID-19). Fifty patients with laboratory-confirmed COVID-19 were divided into two groups: including lopinavir/ritonavir group (34 cases) and arbidol group (16 cases). Lopinavir/ritonavir group received 400mg/100mg of Lopinavir/ritonavir, twice a day for a week, while the arbidol group was given 0.2g arbidol, three times a day. Data from these patients were retrospectively analyzed. The cycle threshold values of open reading frame 1ab and nucleocapsid genes by RT-PCR assay were monitored during antiviral therapy. None of the patients developed severe pneumonia or ARDS. There was no difference in fever duration between the two groups (P=0.61). On day 14 after the admission, no viral load was detected in arbidol group, but the viral load was found in 15(44.1%) patients treated with lopinavir/ritonavir. Patients in the arbidol group had a shorter duration of positive RNA test compared to those in the lopinavir/ritonavir group (P<0.01). Moreover, no apparent side effects were found in both groups. In conclusion, our data indicate that arbidol monotherapy may be superior to lopinavir/ritonavir in treating COVID-19
    corecore